balance equationreview2025-10-31
Difference 6967000000 exceeds tolerance 12727000.000. Presentation or filing-vintage differences need review.
Revenue
$6.95B
Fiscal year ended 2025-10-31Operating income
$1.48B
Fiscal year ended 2025-10-31Free cash flow
$1.15B
Fiscal year ended 2025-10-31AGILENT TECHNOLOGIES, INC. (A) reported revenue of $6.95B and net income of $1.30B for the fiscal year ended 2025-10-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from AGILENT TECHNOLOGIES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.
Income
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.95B | $6.51B | $6.83B | $6.85B | $6.32B | $5.34B | $5.16B | $4.91B | $4.47B | $4.20B |
| Cost of revenue | $3.30B | $2.98B | $3.37B | $3.13B | $2.91B | $2.50B | $2.36B | $2.23B | $2.07B | $2.00B |
| Gross profit | $3.64B | $3.54B | $3.46B | $3.72B | $3.41B | $2.84B | $2.80B | $2.68B | $2.40B | $2.20B |
| Operating income | $1.48B | $1.49B | $1.35B | $1.62B | $1.35B | $846.00M | $941.00M | $904.00M | $807.00M | $615.00M |
| Net income | $1.30B | $1.29B | $1.24B | $1.25B | $1.21B | $719.00M | Unavailable | Unavailable | Unavailable | Unavailable |
| Research & development | $455.00M | $479.00M | $481.00M | $467.00M | $441.00M | $495.00M | $404.00M | $387.00M | $341.00M | $329.00M |
| Weighted-average diluted shares | shares 285.00M | shares 291.00M | shares 296.00M | shares 300.00M | shares 307.00M | shares 312.00M | shares 318.00M | shares 325.00M | shares 326.00M | shares 329.00M |
| Pretax income | $1.44B | $1.52B | $1.34B | $1.50B | $1.36B | $842.00M | $919.00M | $946.00M | $803.00M | $544.00M |
| Income tax expense | $132.00M | $232.00M | $99.00M | $250.00M | $150.00M | $123.00M | -$152.00M | $630.00M | $119.00M | $82.00M |
| Diluted EPS | $4.57 | $4.43 | $4.19 | $4.18 | $3.94 | $2.30 | $3.37 | $0.97 | $2.10 | $1.40 |
| Selling, general & administrative | $1.71B | $1.57B | $1.63B | $1.64B | $1.62B | $1.50B | $1.46B | $1.39B | $1.25B | $1.25B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.79B | $1.33B | $1.59B | $1.05B | $1.48B | $1.44B | $1.38B | $2.25B | $2.68B | $2.29B |
| Total assets | $12.73B | $11.85B | $10.76B | $10.53B | $10.70B | $9.63B | $9.45B | $8.54B | $8.43B | $7.79B |
| Current assets | $4.59B | $3.96B | $4.19B | $3.78B | $3.80B | $3.42B | $3.19B | $3.85B | $4.17B | $3.64B |
| Total liabilities | $5.99B | $5.95B | $4.92B | $5.23B | $5.32B | $4.75B | $4.70B | $3.97B | $3.59B | $3.55B |
| Current liabilities | $2.35B | $1.90B | $1.60B | $1.86B | $1.71B | $1.47B | $2.08B | $1.17B | $1.26B | $945.00M |
| Total equity incl. NCI | -$226.00M | -$305.00M | -$327.00M | $5.30B | $5.39B | $4.87B | $4.75B | $4.57B | $4.84B | $4.25B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $1.02B | $972.00M | $1.03B | $1.04B | $830.00M | $720.00M | $679.00M | $638.00M | $575.00M | $533.00M |
| Accounts receivable | $1.49B | $1.32B | $1.29B | $1.40B | $1.17B | $1.04B | $930.00M | $776.00M | $724.00M | $631.00M |
| Goodwill | $4.47B | $4.48B | $3.96B | $3.95B | $3.98B | $3.60B | $3.59B | $2.97B | $2.61B | $2.52B |
| Long-term debt | $3.05B | $3.34B | $2.74B | $2.73B | $2.73B | $2.28B | $1.79B | $1.80B | $1.80B | $1.90B |
| Accounts payable | $570.00M | $540.00M | $418.00M | $580.00M | $446.00M | $354.00M | $354.00M | $340.00M | $305.00M | $257.00M |
Cash flow
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.56B | $1.75B | $1.77B | $1.31B | $1.48B | $921.00M | $1.02B | $1.09B | $889.00M | $793.00M |
| Capital expenditures | $407.00M | $378.00M | $298.00M | $291.00M | $188.00M | $119.00M | $155.00M | $177.00M | $176.00M | $139.00M |
| Investing cash flow | -$394.00M | -$1.26B | -$310.00M | -$338.00M | -$749.00M | -$147.00M | -$1.59B | -$705.00M | -$304.00M | -$238.00M |
| Financing cash flow | -$715.00M | -$752.00M | -$930.00M | -$1.37B | -$696.00M | -$717.00M | -$299.00M | -$797.00M | -$202.00M | -$268.00M |
| Net change in cash | $459.00M | -$261.00M | $537.00M | -$434.00M | $43.00M | $59.00M | -$866.00M | -$432.00M | $391.00M | $286.00M |
| Stock-based compensation | $128.00M | $129.00M | $111.00M | $125.00M | $110.00M | $83.00M | $72.00M | $70.00M | $60.00M | $58.00M |
| Common dividends paid | $282.00M | $274.00M | $265.00M | $250.00M | $236.00M | $222.00M | $206.00M | $191.00M | $170.00M | $150.00M |
| Common share repurchases | $425.00M | $1.15B | $575.00M | $1.14B | $788.00M | $469.00M | $723.00M | $422.00M | $194.00M | $434.00M |
| Depreciation & amortization | $288.00M | $257.00M | $271.00M | $317.00M | $321.00M | $308.00M | $238.00M | $210.00M | $212.00M | $246.00M |
Derived
| Metric | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $1.15B | $1.37B | $1.47B | $1.02B | $1.30B | $802.00M | $866.00M | $910.00M | $713.00M | $654.00M |
| Gross margin | 52.4% | 54.3% | 50.7% | 54.4% | 53.9% | 53.1% | 54.3% | 54.5% | 53.6% | 52.3% |
| Operating margin | 21.3% | 22.9% | 19.8% | 23.6% | 21.3% | 15.8% | 18.2% | 18.4% | 18.0% | 14.6% |
| FCF margin | 16.6% | 21.1% | 21.6% | 14.9% | 20.5% | 15.0% | 16.8% | 18.5% | 15.9% | 15.6% |
| SBC / revenue | 1.8% | 2.0% | 1.6% | 1.8% | 1.7% | 1.6% | 1.4% | 1.4% | 1.3% | 1.4% |
| Current ratio | 1.96x | 2.09x | 2.61x | 2.03x | 2.22x | 2.33x | 1.53x | 3.29x | 3.30x | 3.85x |
| Revenue YoY growth | 6.7% | -4.7% | -0.2% | 8.4% | 18.4% | 3.4% | 5.1% | 9.9% | 6.4% | Unavailable |
| Net margin | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% | 13.5% | Unavailable | Unavailable | Unavailable | Unavailable |
| R&D / revenue | 6.5% | 7.4% | 7.0% | 6.8% | 7.0% | 9.3% | 7.8% | 7.9% | 7.6% | 7.8% |
| CapEx / revenue | 5.9% | 5.8% | 4.4% | 4.2% | 3.0% | 2.2% | 3.0% | 3.6% | 3.9% | 3.3% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | 0.52x | 0.51x | 0.47x | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 9.2% | 15.3% | 7.4% | 16.6% | 11.0% | 14.6% | -16.5% | 66.6% | 14.8% | 15.1% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open A in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-09-01View SEC filing
10-Q · Filed 2026-06-01View SEC filing
10-Q · Filed 2026-03-03View SEC filing
10-K · Filed 2025-12-22View SEC filing
10-Q · Filed 2025-08-29View SEC filing
10-Q · Filed 2025-06-02View SEC filing
Reconciliation checks needing review
3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2024-10-31
Difference 6203000000 exceeds tolerance 11846000.000. Presentation or filing-vintage differences need review.
balance equationreview2023-10-31
Difference 6172000000 exceeds tolerance 10763000.000. Presentation or filing-vintage differences need review.